Alnylam Pharmaceuticals (ALNY) Stock Price vs Net Income
Open the interactive overlay on autario.com.
Between Q3 2020 and Q3 2021, Alnylam's net loss narrowed from -$890.9 million to -$837.9 million, an improvement of approximately $53 million. Over that same period, the stock price rose from roughly $125 to $189, a 51% gain. Despite the company remaining unprofitable, the stock's strong appreciation indicates investors repriced the company at a significantly higher valuation relative to its operating losses. The broader 22-year window shows a pronounced negative correlation of -0.73 between net income and stock price: the stock climbed from $7 in 2004 to $285 by June 2026 while cumulative losses deepened into the hundreds of millions of dollars, demonstrating that the market valued future profit potential rather than current earnings.
Trailing-12-month Net Income was -$837.9M as of 2021-09-30 (10-Q); the stock traded at $188.81. Not enough overlapping price and reporting history yet for a year-over-year comparison.
Latest close: 287.77 USD (2026-06-02).
Net Income | recent SEC reports
| Report date | Net Income | Period |
|---|
| 2021-09-30 | -837.9M USD | Q3 10-Q |
| 2021-06-30 | -886.7M USD | Q3 10-Q |
| 2021-03-31 | -876.4M USD | Q3 10-Q |
| 2020-12-31 | -858.3M USD | FY 10-K |
| 2020-09-30 | -890.9M USD | Q3 10-Q |
| 2020-06-30 | -846.2M USD | Q3 10-Q |
| 2020-03-31 | -886.4M USD | Q3 10-Q |
| 2019-12-31 | -886.1M USD | FY 10-K |
Sources: autario.com/data/stock-alny-alnylam-pharmaceuticals-daily-prices · autario.com/data/alnylam-pharmaceuticals-net-income-sec-filings | data verified and hosted on autario.com.